Corrigendum : PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise, Lorenz (University Medical Center Hamburg-Eppendorf)
Piseddu, Ignazio (Ludwig-Maximilians-Universität München)
Vonderlin, Joscha (Charité-Universitätsmedizin Berlin)
Tjwa, Eric T. (Radboud Institute for Molecular Life Sciences)
Buescher, Gustav (European Reference Network on Hepatological Diseases)
Meunier, Lucy (Hôpital St-Eloi (Montpellier, França)))
Goeggelmann, Pia (University Hospital Regensburg)
Fianchi, Francesca (Università Cattolica del Sacro Cuore)
Dumortier, Jérôme (Université de Lyon)
Riveiro Barciela, Mar (Hospital Universitari Vall d'Hebron)
Gevers, Tom J. G. (Maastricht University)
Terziroli Beretta-Piccoli, Benedetta (King's College Hospital NHS Foundation Trust)
Londoño, Maria-Carlota (Hospital Clínic i Provincial de Barcelona)
Frankova, Sona (Institute for Clinical and Experimental Medicine (Praga, Txèquia))
Roesner, Thomas (University Medical Center Hamburg-Eppendorf)
Joerg, Vincent (University Medical Center Hamburg-Eppendorf)
Schmidt, Constantin (University Medical Center Hamburg-Eppendor)
Glaser, Fabian (University Medical Center Hamburg-Eppendorf)
Fründt, Thorben W. (University Medical Center Hamburg-Eppendorf)
Lohse, Ansgar W. (University Medical Center Hamburg-Eppendorf)
Huber, Samuel (University Medical Center Hamburg-Eppendorf)
von Felden, Johann (University Medical Center Hamburg-Eppendorf)
Sebode, Marcial (University Medical Center Hamburg-Eppendorf)
Schulze, Kornelius (University Medical Center Hamburg-Eppendorf)
Universitat Autònoma de Barcelona

Data:	2024
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Autoimmune disease (AID) ; Immune checkpoint inhibitors (ICI) ; Autoimmune liver diseases (AILD) ; Immune related adverse effects (irAEs) ; PD-1/PD-L1 immune checkpoint inhibitors ; Autoimmune hepatitis (AIH) ; Primary sclerosing cholangites (PSC) ; Primary biliary cholangitis (PBC)
Publicat a:	Frontiers in immunology, Vol. 15 (january 2024) , ISSN 1664-3224
Obra relacionada:	Kocheise, Lorenz; Piseddu, Ignazio; Vonderlin, Joscha; [et al.]. «PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease». Frontiers in immunology, Vol. 14 (january 2024) https://doi.org/10.3389/fimmu.2023.1326078

Article original: https://ddd.uab.cat/record/304817
DOI: 10.3389/fimmu.2024.1369747
PMID: 38327519

2 p, 249.6 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats